PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2010 July 30.
Published in final edited form as:
PMCID: PMC2912728
NIHMSID: NIHMS219234

Alum induces innate immune responses through macrophage and mast cell sensors, but these are not required for alum to act as an adjuvant for specific immunity.1,2

Abstract

To understand more about how the body recognizes alum we characterized the early innate and adaptive responses in mice injected with the adjuvant. Within hours of exposure, alum induces a type 2 innate response characterized by an influx of eosinophils, monocytes, neutrophils, DCs, NK cells and NKT cells. In addition, at least thirteen cytokines and chemokines are produced within 4 hours of injection including IL-1β and IL-5. Optimal production of some of these, including IL-1β, depends upon both macrophages and mast cells, while production of others, such as IL-5, depends on mast cells only, suggesting that both of these cell types can detect alum. Alum induces eosinophil accumulation partly through the production of mast cell derived IL-5 and histamine. Alum greatly enhances priming of endogenous CD4 and CD8 T cells independently of mast cells, macrophages and of eosinophils. In addition, antibody levels and Th2 bias was similar in the absence of these cells. We found that the inflammation induced by alum was unchanged in caspase-1 deficient mice, which cannot produce IL-1β. Furthermore, endogenous CD4 and CD8 T cell responses, antibody responses and the Th2 bias were also not impacted by the absence of caspase-1 or NLRP3. These data suggest that activation of the inflammasome and the type 2 innate response orchestrated by macrophages and mast cells in vivo are not required for alum's adjuvant effects on endogenous T and B cell responses.

Keywords: innate immune responses, vaccine adjuvant, eosinophils, TLR, NLR

Introduction

Aluminum salts, here referred to collectively as alum, have been used for almost a century to enhance antibody responses in animals and humans with very little understanding about how they mediate their effects on the immune system (1). In human vaccines, aluminum hydroxide, aluminum phosphate and aluminum sulfate are used and the choice of the formulation depends on how well it adsorbs the protein components of the vaccine. Traditionally, all of the adjuvant effects of alum have been attributed to its ability to prolong antigen exposure to the immune system. It is now clear, however, that alum can be recognized by the innate immune system leading to multiple downstream effects including, perhaps, its ability to act as an immunological adjuvant.

Alum elicits a type 2 inflammatory response, characterized by the accumulation of eosinophils at the site of injection in vivo, and this may contribute to the effects of alum on specific immune responses (2). The eosinophils increase MHCII levels and signaling in B cells via IL-4 and promote early IgM responses. Alum also induces the conversion of monocytes into antigen presenting dendritic cells (DCs) (3).

A number of studies have investigated how alum achieves these inflammatory effects. It is known that engagement of toll-like receptors (TLRs) by their ligands, such as LPS, stimulates innate immunity and has powerful adjuvant effects on specific immune responses(4). However, several studies have shown that alum's ability to act as an adjuvant does not depend on either MyD88 or TRIF, adaptor molecules in the signaling pathways that act downstream of TLR ligation(5, 6).

Other pattern recognition receptors such as the NOD-like receptors (NLRs) can also promote innate responses that, in turn, stimulate specific immunity (4) (7-10). Upon activation, members of the NLR family, such as NLRP3, form complexes with ASC and pro-caspase-1. The complex formed by these molecules is referred to as the inflammasome. The NLRP3 inflammasome is activated by a number of materials, including alum (11-15). Its activation may be caused directly by the material in question, or indirectly via the products of cell damage induced by the material. Such products include uric acid crystals and/or enzymes released by lysosomes in damaged cells (14, 16). Whatever the cause of inflammasome activation, the consequences include production of active caspase-1 thus conversion of inactive precursor cytokines of the IL-1 family, including IL-1β, IL-18 and IL-33, to their active forms (17). Since these cytokines are potent stimulators of adaptive responses in some contexts (7-10), the NLRP3 inflammasome is an attractive candidate as and intermediary of alum's adjuvant effects.

Several reports have in fact come to that conclusion, showing that the ability of alum to induce migration of antigen loaded DCs to the LN (3) or to increase antibody production (12, 13), or even to induce cellular infiltrates (3, 12) is greatly reduced in animals that lack NLRP3 or other components of the inflammasome, ASC or caspase-1. Moreover, some studies have shown that uricase inhibits the effect of alum on antigen presentation and T cell priming (3), suggesting that uric acid is involved in the activation of the NLRP3 inflammasome by alum. However, although it is universally agreed upon that alum's ability to induce IL-1β production depends on the NLRP3 inflammasome (3, 12-15), some studies have found no role for NLRP3 in the ability of alum to enhance IgG antibody responses (3, 15). Such results are supported by the early findings, mentioned above, that MyD88, a required intermediary in the signaling pathways of IL-1-related cytokines, is not needed for alum to improve antibody responses(5, 6).

Here, we decided to study the effects of alum on innate and specific immunity in more depth, to find out which cells respond most immediately to the introduction of alum into the body and which of the effects of alum depend on the NLRP3 inflammasome. Our results show that many proinflammatory cytokines and chemokines are rapidly produced in vivo after exposure to alum. Eosinophils, neutrophils, monocytes, NK cells, NKT cells and DCs are rapidly recruited to the site of injection. Simultaneously, mast cell, macrophage and B cell numbers at the site of injection fall. The recruitment of eosinophils was promoted by both macrophages and mast cells, the latter cells via their alum-induced production of IL-5 and histamine, but did not require the inflammasome component, caspase 1.

Alum not only induced enhanced endogenous CD4 T cell responses and antibody production but also enhanced CD8 T cell priming. None of these effects of alum on the specific immune response required macrophages, mast cells, or eosinophils, or, most significantly, the inflammasome components, NLRP3 and caspase 1. Only IL-1β production was affected by the absence of inflammasome activity. Thus, although mast cells and macrophages are early sensors of alum, and in spite of the fact that these cells make many stimulatory substances in response to alum, they are not required for alum's adjuvant effects. Furthermore, although the NLRP3 inflammasome is required for optimal IL-1β production following exposure to alum in vivo, alum promotes its effects on CD4 and CD8 T cell priming and enhancing antibody responses by mechanisms that are independent of the inflammasome.

Materials and Methods

Mice

Wild-type (WT) C57BL/6 (B6), WT BALB/c, CCR3-/-, 5-Lipoxygenase-/-, 15-Lipoxygenase-/-, GATA1Δ and W/+ and Wv/+ breeder mice were purchased from The Jackson Laboratory (Bar Harbor, ME). B6 IL-4 reporter (4Get) mice were obtained from Dr. Richard Locksley (University of California at San Francisco, CA). Phil Tg mice were provided by Dr. Jamie Lee (Mayo Clinic, Scottsdale, Arizona). BLT1-/- mice developed by Dr. Bodduluri Haribabu (James Graham Brown Cancer Center, Louisville, Kentucky) and IL5-/- mice were obtained from Dr. Erwin Gelfand at National Jewish Medical Center (NJMC), Denver CO. Caspase-1 +/- mice generated by Dr. Richard Flavell were provided with permission by Dr. Kenneth Rock (University of Massachusetts Medical Center, Boston, MA) and were bred in house to generate caspase-1 +/-, +/+ and -/- mice for experiments. NLRP3-/- mice, backcrossed for over 9 generations onto a B6 background, were obtained from Dr. Richard Flavell (Yale University, New Haven, CT). All animals were housed and maintained at the Biological Resource Center at NJMC in accordance with the research guidelines of the Institutional Animal Care & Use Committee.

Antibodies and Reagents

Alum was precipitated in the laboratory as previously described (18) and endotoxin levels in the material were determined to be <1ng/ml using the Limulus amebocyte lysate assay (LAL) (Endpoint Chromogenic LAL, Lonza). Alhydrogel was purchased from Accurate Chemical and Imject from Pierce and endotoxin levels were determined to be <1ng/injection using the LAL. The following monoclonal antibodies were purchased from BD Biosciences: PE αCD19 (1D3), PE αNK1.1 (PK136), FITC αCD11c (HL3), PE αSiglec F (E50-2440), PE-Cy7 αCD117 (2B8), AF647 αCCR3 (83103), PerCP αGr1 (RB6-8C5), APC αTCRβ (H57-597), APC-Cy7 αCD4 (GK1.5), PerCP αCD8 (536.7), and FITC αCD62L (MEL-14). FITC αFcERI (MAR-1), PB αF480 (BM8), PB αB220 (RA3-6B2), and PE-Cy7 αCD44 (IM7) were purchased from eBioscience. PE labeled αGalCer mouse CD1d tetramers were produced as previously described in the laboratory of Dr. Laurent Gapin (19). PE labeled IAb/3K tetramer and APC labeled Kb/SIINFEKL tetramers were produced as described in our laboratory (20, 21). 3K-Ova was generated using the Imject Maleimide Activated Ova kit from Pierce Biotechnology and a cysteine linked 3K peptide (FEAQKAKANKAVDGGGC) purchased from Genemed. Endotoxin free ovalbumin protein was isolated as previously described (22) by and provided generously by Ross Kedl at NJRC. The Proteome Profiler Mouse Cytokine Array Panel A kit was purchased from R&D Systems. Cobra venom factor (CVF) from Naja naja kaouthia was purchased from Calbiochem. Clodronate and PBS containing liposomes were synthesized using Cl2MDP (clodronate) a gift of Roche Diagnostics, Phosphatidylcholine, obtained from Lipoid GmbH, (Ludwigshafen,Germany) and cholesterol purchased from Sigma, as previously described (23). J113863 and UCB35625 were purchased from Tocris Bioscience. Neutralizing IL-5 monoclonal antibody was purified from TRFK5 hybridoma supernatants (24). WEB2086 and CV-3968, were purchased from Biomol. Pyrilamine and famotidine, and G-200 Sephadex beads were purchased from Sigma. Diphtheria toxoid and toxin were both purchased from List Biological Laboratories, Inc.

Injections

2-5 mg of Alhydrogel or, in some experiments, alum precipitated in our laboratory were injected i.p. or i.m.. We did not notice significant differences between the innate response induced by these two different formulations of alum at 18 or 24 hours (data not shown). 50μl of the 7mg/ml liposomal clodronate suspension was injected i.p. 24 h prior to alum or PBS injection. In some experiments mice were immunized i.p or i.m (into the hind calf muscle) with 10μg 3K-Ova or diphtheria toxoid precipitated in 2mg Alhydrogel or Imject alum as noted in the figure legends. For treatment of mice with J113863 or UCB35625 inhibitors, mice were injected i.p with 10mg/kg of each inhibitor 2 h prior to injection with either PBS or alum. For in vivo neutralization of IL-5, we injected 500μg of αIL5 antibody i.v. 24 h prior to injection with PBS or alum. Complement depletion was induced by three i.p. injections of 4 U of CVF at 12 h intervals with the last injection 12 h before injection of alum. This treatment resulted in ~90% depletion of complement. Famotidine (200μg/mouse) and pyrilamine (100μg/mouse) were injected into mice i.p. 1 h prior to injection of PBS or alum. For inhibition of PAF, mice were treated 1 h prior to PBS or alum treatment with WEB2086 (100μg/mouse) or CV-3968 (100μg/mouse) i.p.

Cell preparation

Peritoneal cells and in some experiments, spleens, were harvested into BSS. In some experiments blood was harvested by cardiac puncture and sera stored at −20° C until analysis. For analysis of CD4 and CD8 cells, spleens were harvested 9 d after immunization and processed into single cell suspensions using nylon mesh. Red cells were lysed using ammonium chloride and nucleated cells enumerated using a Coulter Counter.

Flow cytometry

Peritoneal cells were incubated with 2.4G2 hybridoma supernatant (αFcγRI/II) and stained using antibodies against the cell surface markers indicated in the figure legends. Splenocytes were stained as described previously (18) with PE labeled IAb/3K and APC labeled Kb/SIINFEKL tetramers, APC-Cy7 αCD4, PB αB220, PB αF480, and PE-Cy7 αCD44 and wells were washed and analyzed on a Cyan Flow Cytometer using Summit Software (DakoCytomation). After data acquisition, data was analyzed using FlowJo software (Tree-Star Inc).

Analysis of cytokines and chemokines

Mice were injected and peritonea washed with 1ml BSS. Cells were spun down and fluid was passed through a 0.2μm syringe filter. Fluid was analyzed using the Proteome Profiler kit (R&D systems) or the histamine enzyme immunoassy (Immuno Biological Laboratories, Inc.) according to the manufacturer's instructions.

ELISAs

96-well Immulon plates (Thermo) were coated with ovalbumin or diphtheria toxin at 10μg/ml in PBS. Plates were washed using ELx405 autoplate washer (BioTek Instruments) and then blocked with 10%FCS/PBS for 2hr RT. Plates were washed and antibody serum samples diluted in 10%FCS/PBS were added to the plates. To determine relative units we used a positive control pooled serum sample from B6 and Balb/c mice that contained ova or diphtheria toxin specific Th2 and Th1 antibody isotypes. The samples were incubated overnight at 4°C. Plates were washed and alkaline phosphatase conjugated anti-IgG1 (X56), anti-IgG2a/c (R19-15), biotinylated anti-IgE (R35-119) (Pharmingen) or anti-kappa (Southern Biotech) detection antibodies were added for 2hr RT. For IgE alkaline phosphatase conjugated streptavadin was added for 1hr RT. Substrate (p-nitrophenyl phosphate) diluted in glycine buffer was added to each well and 405nm absorbance values were collected on Elx808 microplate reader.

Statistics

Statistical significance between selected groups was determined using Student's two tailed T test and in some experiments, a one-way ANOVA was performed with Bonferonni post hoc test. All statistical analysis was done using GraphPad Prism software version 4.

Results

Alum induces rapid accumulation of innate IL-4 expressing cells that are primarily composed of eosinophils

Alum usually generates Th2-related specific immune responses. In part this bias is caused by alum's ability to induce production of IL-4. IL-4 made in response to alum is not required to drive Th2 responses but rather, acts by suppressing Th1-related phenomena, leading to a more polarized immune response (18, 25). Because of this we tracked the appearance of type 2 innate cells after alum injection. To follow inflammation following exposure to alum, we used a peritoneal model in order to be able to follow cell infiltrates and production of soluble mediators in the peritoneal cavity (18). Alum was into mice that express GFP from an internal ribosomal entry site immediately downstream of the IL-4 stop site (4Get mice) (26, 27). Previous experiments using these mice, showed that Gr1intIL-4 expressing cells are recruited to the peritoneal cavity in response to i.p. injection of alum by 24 hours (18).

To characterize the nature of innate IL-4 expressing cells that respond to alum, 4Get mice were injected i.p. with alum and IL-4+ (GFP+) cells at the site of injection examined 24 hours later for markers of eosinophils (Siglec F), mast cells (cKit) and basophils (FcERI) (Figure 1A). In PBS injected mice, most of the IL-4 expressing cells in the peritoneal cavity were mast cells (Siglec Fnegckit+) and only a few were eosinophils (Siglec F+ckitneg) (Fig. 1A, left column, Fig. 1C). The mast cells dropped in numbers after alum injection (Fig. 1A, right hand column and Fig. 1B). In alum injected mice, almost all of the IL-4 expressing cells were eosinophils (Fig. 1A) and these cells co-expressed low levels of Gr1 (data not shown). Consistent with previous findings (2, 3), the numbers of eosinophils rose after alum administration, beginning their increase a few hours after the disappearance of the mast cells (Fig. 1B). Basophils also express IL-4 and have been described to play a role in Th2 responses (28-32). We did not find any basophils (FcER1+ckitneg) in the peritoneum prior to or following injection of alum (Fig. 1C). Thus, almost all of the innate IL-4+ cells in alum-induced inflammation had staining characteristics of eosinophils (Siglec F+ckitneg) (Fig. 1A, right column).

Figure 1
Characterization of the innate response 24 hours after injection with alum

Further examination of the inflammation induced by alum confirmed that, as described previously (3), the numbers of peritoneal macrophages (F4/80hi) fell following alum injection (Fig. 1A, B), and with the same kinetics as the mast cells (Fig. 1B). As predicted (3), the numbers of neutrophils (Gr1hiSSChi), Gr1 intermediate (Gr1int) Ly6ChiSSClo monocytes (Supplemental F. 1), and DCs (Supplemental Fig. 2B) all increased in response to alum. In addition, NK cells and NKT cell also increased in number (Supplemental Fig. 2C,D), while T cell numbers were unchanged and B cell numbers dropped modestly (Supplemental Fig. 2A and C).

Induction of multiple chemokines and cytokines occurs within hours of exposure to alum

To characterize the soluble factors released during the inflammatory response induced by alum, we used a multiplex membrane bound ELISA assay to test the peritoneal fluid from mice injected previously with PBS or alum. A time course showed that the amounts of induced factors peaked 4 hours after injection (data not shown). In alum injected mice, we detected increased levels of 14 soluble factors including the Th2-associated cytokine IL-5 (Fig. 2A). No Th1- or Th17-associated factors were detected over background levels (Fig. 2A). In addition to IL-1β (Fig. 2A and (11)), several other inflammation associated cytokines were elevated after alum injection, including IL-1ra and IL-6, while levels of IL-1α, TNFα, and IL-10 remained unchanged (Fig. 2A). In addition to MCP-1, KC and eotaxin, which have been shown to increase after alum injection (Fig. 2B and (11)), alum induced increased levels of additional cell-attractive proteins, including C5a, MIG, IP10, and MIP2 (Fig. 2B).

Figure 2
Cytokines and chemokines induced 4 hours after exposure to alum

Macrophages and mast cells promote type 2 inflammation

The rapid disappearance of macrophages and mast cells after alum injection may result from activation, adherence to the peritoneal cell wall, mast cell degranulation, or cell death as has been observed in macrophages exposed to alum in vitro (14), and suggests that these cells may respond rapidly to alum and participate in the production of cytokines following exposure to alum. To test the idea, macrophage or mast cell deficient mice were injected with alum and the appearance of cytokines and chemokines in the peritonea analyzed 4 hours later. To deplete macrophages, WT B6 mice were injected with the macrophage depleting agent, clodronate liposomes (33). As expected, liposomal clodronate was highly efficient at depleting macrophages, but not mast cells, DC, neutrophils, or eosinophils (Supplemental Fig. S3). To determine the role of mast cells, we used mast cell deficient W/Wv mice.

Of the cytokines and chemokines that were elevated significantly above controls by alum injection (Fig. 2), the amounts of IL-1β, IL-1Ra, IL-6, and the chemokine, eotaxin, were all significantly decreased in clodronate liposome treated mice (Fig. 3, left column). However, to our surprise, all of these factors were also decreased in alum injected mast cell deficient mice. This result suggests that these factors are potentially made by both macrophages and mast cells in response to alum or that interactions between these cell types promote optimal cytokine production. In contrast, levels of IL-5, IL-16, G-CSF, KC, and MIP2 were all decreased in mast cell deficient but not macrophage depleted mice (Fig. 3, middle column). Finally the levels of MIG, IP10, KC and MCP-1 were not significantly affected by absence of either macrophages or mast cells (Fig. 3, right column) suggesting that they may be made by other cell types including endothelial cells, fibroblasts, neutrophils and/or DC (34). These results suggest a complex inflammatory response to alum mediated by multiple cell types that culminates in the production of a wide range of soluble mediators.

Figure 3
Macrophages and mast cells are sensors of alum in vivo

Alum promotes mast cell mediated recruitment of eosinophils via IL-5 and histamine

In mast cell deficient mice, we found a partial reduction in the number of eosinophils recruited in response to alum, compared to the numbers in WT mice (Fig. 4A). IL-5, which is decreased in the mast cell deficient mice (Fig. 3), is known to play a role in the recruitment of eosinophils in response to other Th2 driving substances such as helminth eggs (35, 36). Eosinophil recruitment did not occur in IL-5-/- mice given alum (data not shown). However, IL-5 is needed for eosinophil development as well as optimal eosinophil movement (35, 37) and therefore lack of IL-5 could have reduced eosinophil accumulation because of reduced numbers of the cells in IL-5-/- mice. To test this, we transiently depleted IL-5 in vivo. Mice were injected with neutralizing anti-IL-5 antibody 1 day before the injection of PBS or alum, and the effect of these treatments on eosinophil accumulation was measured 24 hours later. We found that blocking IL-5 resulted in a reduction in the accumulation of eosinophils in response to alum (Fig. 4B). In contrast, anti-IL-5 did not further reduce the small numbers of eosinophils that appear in response to alum in W/Wv mice (Fig. 4D). These data suggest that, like helminth eggs (36), alum attracts eosinophils by promoting mast cell dependent IL-5 production.

Figure 4
Mast cells and macrophages are needed for accumulation of eosinophils in response to alum

Mast cell degranulation and the release of histamines have been shown to be involved in the recruitment of inflammatory cells in response to implanted biomaterial particles (38) and have been implicated in eosinophil recruitment as well (39). Accordingly, we were able to detect histamine release in the peritoneal fluid of alum injected WT mice within 10 minutes of alum injection but not in similarly treated mast cell deficient W/Wv mice (Fig. 4C). To evaluate whether histamine production had any impact on eosinophil recruitment, we used a combined treatment of famotidine and pyrilamine to block signaling through the H1 and H2 receptors. Treatment of mice with these antihistamines 2 hours prior to exposure to alum resulted in a partial reduction in the total number of eosinophils recruited in response to alum particles in WT but not mast cell deficient W/Wv mice (Fig. 4D). Treatment of mice with αIL-5 antibody together with antihistamines did not have an additive effect (Fig. 4D). Thus mast cells, IL-5 and histamine all promote eosinophil recruitment in response to alum and appear to be acting together.

Despite the reduced influx of eosinophils in the absence of mast cells, IL-5 or histamine receptor signaling, there still were increased numbers compared to those in PBS injected control mice, therefore an alternative pathway must promote eosinophil responses to alum. We observed a marked reduction of eosinophils in mice depleted of macrophages (Fig. 4E), suggesting that they also respond to alum by promoting eosinophil recruitment. Surprisingly, several factors expected to play a role, including eotaxin, platelet activating factor, complement, and leukotriene B4, were not required for the alum induced eosinophil response (Supplemental Figs. 4, 5). Therefore, besides the mast cell/IL-5/histamine pathway, there are other pathways involved in the eosinophil response to alum. Macrophages may promote eosinophil recruitment through as yet undefined factors, or perhaps several soluble factors tested here, may act redundantly.

Mast cells, macrophages and eosinophils are not required for enhanced priming of T cells, Th2 bias or antibody responses to alum

Our data suggest that mast cells and macrophages sense the presence of alum and respond by producing a number of inflammatory factors, chemokines and cytokines. Because soluble factors, such as IL-1β, have been implicated in alum's adjuvant effects on B and T cells (11-13), it was possible that this is an important early step in alum's adjuvant activity in vivo. To test this idea, we first tracked CD4 and CD8 T cell responses in untreated or clodronate liposome injected WT (Kit+/+) or W/Wv mice. To avoid the artifacts that might occur if transferred T cells expressing transgenic TCRs are used (40, 41), we followed endogenous antigen specific CD4 and CD8 T cell responses using peptide/MHC tetramers. In order to do this we immunized mice with the 3K peptide (21, 42) conjugated to ovalbumin (ova) protein (3K-ova), and measured endogenous CD4 T cell responses with 3K/IAb tetramers and CD8 T cell responses to an ova peptide/Kb with SIINFEKL/Kb tetramers (21, 42). We found that injection of WT mice with 3K-ova adsorbed to alum promoted endogenous CD4 T cell responses (18). Moreover, this antigen/adjuvant combination also, to our surprise, greatly enhanced CD8 T cell priming (Fig. 5B,C). We found no difference in the percentage (Fig. 5A,B) or total number (Fig. 5C) of antigen-specific CD4 or CD8 T cells primed by alum in mice lacking macrophages, mast cells, or both cell types. Likewise, absence of mast cells had no effect on the ability of alum to induce total Ig and IgG1 primary or secondary responses to ova, or IgG2c secondary responses to the same antigen (Fig. 5E).

Figure 5
Mast cells and macrophages are not required for alum to enhance adaptive immunity

Similar experiments were performed in B6 or B6 4Get mice in which macrophages were depleted with clodronate liposomes. Lack of macrophages had no effect on the size of the CD4 and CD8 T cell response (Fig. 5C), the Th2 nature of the response (Fig. 5D) or the size and nature of the antibody response to 3K-ova plus alum (Fig. 5E).

Previous results suggest that IL-4 is not required to initiate Th2 responses to alum, but may suppress Th1 responses (25). Treatment of mice with a Gr1 specific antibody had a similar but partial effect on the bias of the response (18). Although Gr1 is expressed at low levels on eosinophils, it is a non-specific marker and may bind to both Ly6G and Ly6C expressing cell types. Thus, we wanted to examine whether adaptive responses were affected in eosinophil deficient mice immunized with alum. We first examined T cell priming and antibody responses in IL-5 deficient mice and found no significant effect on the total number of antigen specific CD4 or CD8 T cells primed compared to WT control animals (Fig. 6A). In addition, we found no effect on the levels of total anti-ova antibody in IL-5 deficient mice or in the levels of IgG1 or IgG2c (Fig. 6B), suggesting that eosinophils neither impact alum's ability to act as an adjuvant nor the bias of the response induced. We also saw no decrease in the levels of ova specific Ig, IgG1 or IgG2c antibody responses in eosinophil deficient Phil mice (Fig. 6C). These mice express diphtheria toxin under the control of the eosinophil peroxidase promoter and are congenitally deficient in eosinophils (43). Finally, we saw no decrease in ova specific Ig, IgG1, IgG2a, and IgE levels in eosinophil deficient GATA1Δ mice that contain a mutation in GATA1 that prevents eosinophil differentiation (44) compared to WT controls (Fig. 6D). The only effect observed was an overall increase in IgE levels in the GATAΔ mice (Fig. 6D).

Figure 6
Eosinophils have no effect on the ability of alum to enhance T cell priming and antibody levels

Thus, macrophage and mast cell sensors appear to play a role only in the inflammatory response to alum and do not participate in the ability of alum to act as an adjuvant for the specific immune response in vivo. While the induction of eosinophils by alum has been shown to promote early IgM responses to alum and alter MHC II mediated intracellular signaling (45), they are unlikely to plan an important role in antibody responses relevant to immunization.

The inflammatory response to alum does not require caspase-1

Recent work by others (11, 12, 15, 46, 47), and our detection of IL-1β in peritoneal exudates (Fig. 3), suggests that alum can activate caspase-1 rapidly in response to alum. Other work has indicated that products of this activation, such as IL-1β family members might contribute to the downstream consequences of alum injection perhaps via effects on DCs (11, 12), while others have found no role for the inflammasome in the adjuvant activity of alum (15). To test whether the inflammasome promotes recruitment of inflammatory cells including those likely to be required for alum's adjuvant effects, we injected caspase-1-/- mice with PBS or alum and examined the numbers of resident and inflammatory cells in their peritoneal cavities 18 hours later. Absence of caspase-1 had no impact on the ability of alum to reduce the numbers of macrophages and mast cells in the peritoneal lavage, or on the alum-induced increases in the numbers of eosinophils, neutrophils, monocytes or DCs in the peritoneal cavity (Fig. 7A). This was observed even though IL-1β production in response to alum was drastically reduced in these same animals (Fig. 7B). This result was surprising, considering the previous report that accumulation of granulocytes, monocytes and DC are dependent upon NLRP3, an adaptor which is thought to mediate its effects by promoting activation of caspase-1 (11).

Figure 7
Induction of eosinophil recruitment by alum in caspase-1 deficient mice is normal

Together, these data strongly suggest that the inflammatory response does not require pathways dependent on caspase-1. The discrepancies between these results and ours are not clearly understood, although they may suggest that another pathway downstream of NLRP3 could be playing a role in early inflammatory responses to alum (11).

The adjuvant effects of alum on T and B cell responses are not dependent on NLRP3 or caspase-1

To examine, in our own hands, the issues surrounding the controversy about the role of the NLRP3 inflammasome in alum induced responses (11-13, 15), we immunized NLRP3-/- and control WT mice and caspase-1+/+ and +/- littermate control mice i.p. with 3K-ova adsorbed to alum and followed their endogenous antigen-specific CD4 and CD8 T cell responses in the spleen and mediastinal LN (the LN that drains the peritoneal cavity (3)), using MHC/tetramers (Fig. 8A-F). Alum improved responses to its accompanying antigen since, as expected, T cell responses were much smaller in animals given antigen without alum (Fig. 8A,B). The absence of NLRP3 or caspase-1 had no effect on the magnitude of CD4 T cell and CD8 T cell responses to antigen plus alum, either in spleen (Fig. 8A,B,E,F) or the mediastinal LN (Fig 8C,D and data not shown). In addition, we assayed antigen specific antibodies in the sera of these mice and found that caspase-1-/- mice had levels of anti-ova IgG1 antibody that were similar to those of heterozygous or WT mice (Fig. 8G). Levels of antigen specific IgG2c were undetectable at this time in all the mice (data not shown). Because these experiments were done very early in the immune response in order to look at T cell priming, the possibility remained that although early IgG1 responses were unaffected, long term antibody responses may be impacted in mice unable to activate caspase-1. However, when we followed antigen specific antibody responses to ova in ova/alum injected caspase-1 +/+, +/- and -/- mice at later time points and during the secondary response, we were unable to see any significant difference in the antibody response (Fig. 8H).

Figure 8
NLRP3 and Caspase-1 are not required for alum to enhance endogenous CD4, CD8 T cell priming and antibody responses to adsorbed antigen

It has been suggested that different laboratories may find different requirements for the NLRP3 inflammasome because they use different alum formulations. To check this, we followed antibody responses to antigen adsorbed to Alhydrogel or Imject alum, and still found no requirement for caspase-1 (Supplemental Fig. 6A). Likewise, the site of sensitization did not govern whether or not caspase-1 were required, since responses to antigen plus alum were unaffected in mice immunized ip followed by intranasal challenge with antigen (Supplemental Fig. 6A,B) or after intramuscular injection of antigen plus alum (Fig. 9A).

Figure 9
Enhanced T cell priming and antibody responses to alum adjuvant are normal in NLRP3 deficient mice

Although, consistent with published reports (5, 6), we found no effect on alum's ability to increase either T cell priming or antibody production in MyD88 deficient mice (data not shown), it was possible that low levels of endotoxin present in our antigen preparation (<1.3ng/injection) could influence our results, and could provide an explanation for the discrepant results regarding the role of the caspase-1 and NLRP3 in the adjuvant activity of alum. To test this, we obtained ova that had no detectible levels of endotoxin by the LAL assay (endotoxin <0.008ng/injection) for immunization. Levels of IgG1 antibodies induced against ova were similar in WT and caspase-1 deficient mice injected with endotoxin free ova plus alum (Fig. 9A,B).

To check that our findings reflected the response to an antigen used in man, we compared primary and secondary antibody responses to diphtheria toxin in WT or NLRP3-/- mice immunized with diphtheria toxoid adsorbed to alum. To control for any potential adjuvant properties of the toxoid alone, we also compared antibody responses induced in the absence of alum. Alum adsorbed diphtheria toxoid greatly enhanced antibody production against diphtheria toxin compared to injection of diphtheria toxoid alone. We confirmed that equivalent amounts of antibody that recognized diphtheria toxin were circulating in WT and NLRP3 deficient mice that had been immunized with diphtheria toxoid adsorbed to alum (Fig. 9E).

Thus overall, we could not find any compulsory role for the inflammasome in the ability of alum to improve T and B cell responses to alum.

Discussion

Alum is a mysterious adjuvant and, in spite of a significant amount of work, many questions about the effects of this material remain. Others have previously shown that macrophages and DCs can respond directly to the presence of alum in vitro through activation of caspase-1 (11, 12, 47). The work described here confirms the finding that macrophages are targets in vivo and extends them to include responses of mast cells, suggesting that both these cell types have the machinery needed to detect alum particles. In addition, our results indicate that other resident cells, perhaps DCs or stromal cells, may also have this capacity, since removal of both macrophages and mast cells from the site of alum injection did not completely ablate responses to the material.

How macrophages and mast cells detect alum is an intriguing question and in fact, alum may be detected in several, non-mutually exclusive ways. A number of in vitro experiments have shown that alum activates the NLRP3 inflammasome in macrophages which, in turn, activates caspase-1 and consequent production of IL-1β. In vitro, but not in vivo, alum's ability to induce IL-1β production requires the additional stimulus of LPS (11, 12). The activation of the NLRP3 inflammasome in macrophages by alum requires intact phagocytic machinery (12) and may involve K+ efflux (12) and may be initiated by so-called frustrated phagocytosis (48), or alternatively, by phagocytosis followed by fracture of lysosomes, release of lysosomal enzymes into the cytosol (14). Some data implicate uric acid in activating the inflammasome and production of IL-1β in vivo (3, 47).

The experiments described in this manuscript show that eosinophil, neutrophil, DC and monocytes cellular infiltrates induced in response to aluminum hydroxide are unaffected by absence of the enzyme, caspase-1, needed to generate IL-1β. The accumulation of one cell type, the eosinophil is promoted in part by mast cell derived IL-5 and histamine (37). Surprisingly, eosinophil accumulation did not require any of the many chemokines, including eotaxin, that are secreted in response to alum administration. Histamine is produced by activated mast cells and basophils, and, since we found so few basophils in peritoneal cavities, this suggested an additional role for mast cells. Eosinophils respond directly to histamine via H4 histamine receptors, while H1 and H2 receptors are expressed by the endothelium (49). The experiments described here showed that eosinophil recruitment was inhibited by antagonists of histamine H1 and H2 receptors. Thus, in this case the histamine probably acted by promoting vascular leakiness, allowing eosinophil migration into the peritoneal cavity, rather than by affecting eosinophils directly.

The processes by which mast cells detect alum are not clear. It is known that alum activates several sets of serum enzymes, including those of the complement cascade (50) and these may activate cells such as macrophages and mast cells. However, although mast cells are activated to release histamine and other factors by complement fragments (51, 52), we here show that depletion of complement does not affect the appearance of eosinophil exudates in response to alum, suggesting that this is not the means whereby mast cells, at least, detect alum.

Despite the ability of mast cells and macrophages to respond to alum particles, their presence has no impact on the downstream adaptive responses initiated by alum. In addition, eosinophils are not required for T cell priming, and do not enhance the magnitude or change the overall nature of the antibody response to alum. Thus, although eosinophils express IL-4, they play no role in the suppression of Th1 associated isotypes that has been observed in IL-4 deficient or Gr1 depleted mice (18, 25). Perhaps T cells themselves, or basophils (28-32), are the important source of IL-4 that mediates this effect in vivo.

We, like some (15), but not all (3, 12, 13) have completely failed to find a connection between inflammasome activation and the adjuvant effects of alum. Our data suggest that this negative result is not due to contamination of our preparations with LPS, or with the type of alum we use, or with the timing or route of alum administration. Thus it seems that responses to antigen plus alum have a variable requirement (in our case, no requirement) for the NLRP3 inflammasome.

There are three, not mutually exclusive, explanations for the discrepant results. One is that subtle experimental differences, such as the precise status of the mice, allow the presence or absence of factors that can substitute for the products of the NLRP3 inflammasome. Assuming that are IL-1-related cytokines are responsible for mediating adjuvant effects, what could these compensating factors be? They are unlikely to be products of alum-activated macrophages, such as IL-6, since macrophages, the major source of alum-induced IL-1β and IL-6 (Fig. 5) are not involved in the adjuvant activity of alum.

Another possibility is that alum enhances immune responses via redundant effects on DCs and is enhanced but not required by the activity of the NLRP3 inflammasome (3). Thus, in one study, alum enhanced trafficking of antigen-bearing monocytes and antigen presentation to a fairly large number of transferred T cell receptor transgenic CD4 T cells in draining lymph nodes, a process that was abrogated by neutralization of IL-1β (3, 11). Despite these effects on antigen presenting cells, however, lack of NLRP3 had no negative effect on antigen specific IgG levels in this study (11), a result that is consistent with our data. Perhaps the dependence of specific immune responses on the NLRP3 inflammasome depends on whether or not APC activity is limiting. In animals containing large numbers of naïve antigen specific T cells, APCs may be limiting and the large immune response may then be dependent on NLRP3 activity for an optimal response. In animals containing small numbers of endogenous antigen specific T cells, NLRP3-mediated stimulation of APCs may not be needed and alum may act through additional pathways to support T cell priming and T dependent antibody responses.

Finally, assuming IL-1β or other related cytokines are the required product of the NLRP3 inflammsome, perhaps they can be produced via other redundant pathways. IL-1β cytokine can be produced by additional enzymes, which include proteases such as proteinase-3, elastase and granzyme A (53). This latter possibility seems unlikely given that IL-1β levels are drastically reduced in alum-injected macrophage deficient or caspase-1 deficient mice (Figs. 3, ,7),7), yet alum's adjuvant activity in these animals is unabated.

Supplementary Material

Supp 3-6

Acknowledgments

We would like to thank the NIH core facility for supplying the biotinylated recombinant CD1d protein and Dr. Laurent Gapin for the assembled αGalCer CD1d tetramers. We would also like to thank Drs. Peter Henson and Leonard Dragone, and the members of the Kappler Marrack laboratory for their intellectual contributions to this project, and especially to Janice White, Frances Crawford, Tibor Vass, and Alexandria David for technical support. We would like to thank Dr. Richard Locksley for the IL-4 reporter mice, Drs. Richard Flavell and Ken Rock for the Caspase-1-/- and NLRP3-/- mice, and Drs. Bodduluri Haribabu and Erwin Gelfand for the BLT1-/- mice.

Footnotes

1This work was supported by USPHS grants AI-18785, AI-52225 and AI 22295.

2Abbreviations: TLR, toll-like receptor; BSS, balanced salt solution; Tg, transgenic; CTM, complete tumor medium; IL, LTB4 Leukotriene B4; PAF, platelet activating factor; MIP, macrophage inflammatory protein; MIG, Monokine induced by gamma interferon; IP10, 10kDa IFN induced protein; KC, keratinocytes-derived chemokine; MCP, monocytes chemotactic protein; PB, pacific blue

References

1. Glenny A, P C, Waddington H, Wallace U. The antigenis value of toxoid precipitated by potassium alum. Journal of Pathology and Bacteriology. 1926;29:38–45.
2. Walls RS. Eosinophil response to alum adjuvants: involvement of T cells in non-antigen-dependent mechanisms. Proc Soc Exp Biol Med. 1977;156:431–435. [PubMed]
3. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008;205:869–882. [PMC free article] [PubMed]
4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–376. [PubMed]
5. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001;2:947–950. [PubMed]
6. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006;314:1936–1938. [PMC free article] [PubMed]
7. Khoruts A, Osness RE, Jenkins MK. IL-1 acts on antigen-presenting cells to enhance the in vivo proliferation of antigen-stimulated naive CD4 T cells via a CD28-dependent mechanism that does not involve increased expression of CD28 ligands. Eur J Immunol. 2004;34:1085–1090. [PubMed]
8. Nakae S, Asano M, Horai R, Sakaguchi N, Iwakura Y. IL-1 enhances T cell-dependent antibody production through induction of CD40 ligand and OX40 on T cells. J Immunol. 2001;167:90–97. [PubMed]
9. Pollock KG, Conacher M, Wei XQ, Alexander J, Brewer JM. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology. 2003;108:137–143. [PubMed]
10. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490. [PubMed]
11. Kool M, Petrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J. Cutting Edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol. 2008;181:3755–3759. [PubMed]
12. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122–1126. [PubMed]
13. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol. 2008;181:17–21. [PMC free article] [PubMed]
14. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–856. [PMC free article] [PubMed]
15. Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol. 2008;38:2085–2089. [PMC free article] [PubMed]
16. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241. [PubMed]
17. Petrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007;19:615–622. [PubMed]
18. McKee AS, Macleod M, White J, Crawford F, Kappler JW, Marrack P. Gr1+IL-4-producing innate cells are induced in response to Th2 stimuli and suppress Th1-dependent antibody responses. Int Immunol 2008 [PMC free article] [PubMed]
19. Matsuda JL, Naidenko OV, Gapin L, Nakayama T, Taniguchi M, Wang CR, Koezuka Y, Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med. 2000;192:741–754. [PMC free article] [PubMed]
20. Crawford F, Kozono H, White J, Marrack P, Kappler J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity. 1998;8:675–682. [PubMed]
21. Willis RA, Kappler JW, Marrack PC. CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci U S A. 2006;103:12063–12068. [PubMed]
22. Adam O, Vercellone A, Paul F, Monsan PF, Puzo G. A nondegradative route for the removal of endotoxin from exopolysaccharides. Anal Biochem. 1995;225:321–327. [PubMed]
23. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83–93. [PubMed]
24. McNamee LA, Fattah DI, Baker TJ, Bains SK, Hissey PH. Production, characterisation and use of monoclonal antibodies to human interleukin-5 in an enzyme-linked immunosorbent assay. J Immunol Methods. 1991;141:81–88. [PubMed]
25. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, Alexander J. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol. 1999;163:6448–6454. [PubMed]
26. Mohrs M, Shinkai K, Mohrs K, Locksley RM. Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter. Immunity. 2001;15:303–311. [PubMed]
27. Voehringer D, Shinkai K, Locksley RM. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity. 2004;20:267–277. [PubMed]
28. Perrigoue JG, Saenz SA, Siracusa MC, Allenspach EJ, Taylor BC, Giacomin PR, Nair MG, Du Y, Zaph C, van Rooijen N, Comeau MR, Pearce EJ, Laufer TM, Artis D. MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol. 2009;10:697–705. [PMC free article] [PubMed]
29. Yoshimoto T, Yasuda K, Tanaka H, Nakahira M, Imai Y, Fujimori Y, Nakanishi K. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol. 2009;10:706–712. [PubMed]
30. Wynn TA. Basophils trump dendritic cells as APCs for T(H)2 responses. Nat Immunol. 2009;10:679–681. [PMC free article] [PubMed]
31. Sokol CL, Chu NQ, Yu S, Nish SA, Laufer TM, Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol. 2009;10:713–720. [PMC free article] [PubMed]
32. McDonald F, Mohrs M, Brewer J. Using bicistronic IL-4 reporter mice to identify IL-4 expressing cells following immunisation with aluminium adjuvant. Vaccine. 2006;24:5393–5399. [PubMed]
33. Claassen I, Van Rooijen N, Claassen E. A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage ‘suicide’ technique. J Immunol Methods. 1990;134:153–161. [PubMed]
34. Mackay CR. Chemokines: immunology's high impact factors. Nat Immunol. 2001;2:95–101. [PubMed]
35. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–174. [PubMed]
36. Sabin EA, Kopf MA, Pearce EJ. Schistosoma mansoni egg-induced early IL-4 production is dependent upon IL-5 and eosinophils. J Exp Med. 1996;184:1871–1878. [PMC free article] [PubMed]
37. Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996;4:15–24. [PubMed]
38. Tang L, Jennings TA, Eaton JW. Mast cells mediate acute inflammatory responses to implanted biomaterials. Proc Natl Acad Sci U S A. 1998;95:8841–8846. [PubMed]
39. He S, Peng Q, Walls AF. Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol. 1997;159:6216–6225. [PubMed]
40. Hataye J, Moon JJ, Khoruts A, Reilly C, Jenkins MK. Naive and memory CD4+ T cell survival controlled by clonal abundance. Science. 2006;312:114–116. [PubMed]
41. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol. 2005;6:793–799. [PMC free article] [PubMed]
42. MacLeod MK, McKee A, Crawford F, White J, Kappler J, Marrack P. CD4 memory T cells divide poorly in response to antigen because of their cytokine profile. Proc Natl Acad Sci U S A. 2008;105:14521–14526. [PubMed]
43. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O'Neill KR, Protheroe C, Pero R, Nguyen T, Cormier SA, Lenkiewicz E, Colbert D, Rinaldi L, Ackerman SJ, Irvin CG, Lee NA. Defining a link with asthma in mice congenitally deficient in eosinophils. Science. 2004;305:1773–1776. [PubMed]
44. Siegle JS, Hansbro N, Herbert C, Yang M, Foster PS, Kumar RK. Airway hyperreactivity in exacerbation of chronic asthma is independent of eosinophilic inflammation. Am J Respir Cell Mol Biol. 2006;35:565–570. [PubMed]
45. Wang HB, Weller PF. Pivotal Advance: Eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol. 2008;83:817–821. [PMC free article] [PubMed]
46. Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine. 2007;25:4575–4585. [PubMed]
47. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol. 2007;178:5271–5276. [PubMed]
48. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–677. [PMC free article] [PubMed]
49. Asako H, Kurose I, Wolf R, DeFrees S, Zheng ZL, Phillips ML, Paulson JC, Granger DN. Role of H1 receptors and P-selectin in histamine-induced leukocyte rolling and adhesion in postcapillary venules. J Clin Invest. 1994;93:1508–1515. [PMC free article] [PubMed]
50. Ramanathan VD, Badenoch-Jones P, Turk JL. Complement activation by aluminium and zirconium compounds. Immunology. 1979;37:881–888. [PubMed]
51. Johnson AR, Hugli TE, Muller-Eberhard HJ. Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology. 1975;28:1067. [PubMed]
52. Erdei A, Kerekes K, Pecht I. Role of C3a and C5a in the activation of mast cells. Exp Clin Immunogenet. 1997;14:16–18. [PubMed]
53. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550. [PubMed]